Frontline Therapy Options
FDA ODAC Recommends Early Use of Cilta-cel and Ide-cel for Treating Relapsed/Refractory Multiple Myeloma
On Friday, March 15, 2024; the U.S. Food and Drug Administration (FDA) held an Oncologic Drugs Advisory Committee (ODAC) meeting to assess the risk-benefit profile
